Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]
Frontiers in Pharmacology, 2013 Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Amit K. Tiwari, Zhe-Sheng eChen
doaj +3 more sources
Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors [PDF]
PharmaceuticsBackground/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation.
Anna I. Malykhina +2 more
doaj +2 more sources
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives [PDF]
Pharmaceuticals, 2023 Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes.
Ahmed K. ElHady +3 more
doaj +2 more sources
Phosphodiesterase-5 inhibitors: Raynaud's and beyond
Indian Journal of Rheumatology, 2017 Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak +3 more
doaj +3 more sources
Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]
Current Sports Medicine Reports, 2017 Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo +8 more
core +5 more sources
Phosphodiesterase-5 inhibitors for erectile function rehabilitation in patients undergoing nerve sparing radical prostatectomy: a scoping review [PDF]
Revista do Colégio Brasileiro de CirurgiõesIntroduction: The aim of this study was to conduct a scoping review on the efficacy of phosphodiesterase-5 inhibitors (PDE-5Is) in rehabilitating erectile function in patients undergoing cavernous nerve sparing radical prostatectomy (NSRP).
GABRIEL CARVALHO ANDRADE GADELHA +1 more
doaj +2 more sources
Identifying Phosphodiesterase‐5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders [PDF]
ChemistryOpenPhosphodiesterase type 5 (PDE5) is a multidomain protein that plays a crucial role in regulating cellular cyclic guanosine monophosphate (cGMP), a key signaling molecule involved in various physiological processes.
Mohd Shahnawaz Khan +5 more
doaj +2 more sources
Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
Molecules, 2023 This study proposed a high-performance thin-layer chromatography (HPTLC) screening method to detect phosphodiesterase 5 (PDE-5) inhibitors as possible adulterant agents in various dietary supplements.
Oana Ramona Cătălina Gheorghiu +7 more
doaj +1 more source
Mirodenafil Prevents Bladder Dysfunction Induced by Chronic Bladder Ischemia in Rats [PDF]
International Neurourology Journal, 2015 Purpose: To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Methods: Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group ...
Hoon Choi +5 more
doaj +1 more source
A review of phosphodiesterase type 5 inhibitors
South African Family Practice, 2014 Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction.
N. Schellack, A. Agoro
doaj +1 more source